Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer

NCT02253459 is registered in ClinicalTrials.gov with Beijing Biostar Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02253459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2014
Completion date
December 15, 2018
Enrollment
405 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer